HAYWARD, Calif., Nov. 10, 2021 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company, today announced that it will release third quarter
financial results before the market opens on Monday, November 15, 2021. AcelRx management will
host a live webcast and conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) on November 15, 2021 to discuss the financial
results and provide an update on the company's business.
The webcast is accessible by visiting the Investors page of the
company's website at www.acelrx.com and clicking on the webcast
link on the Investors home page. The webcast will be accompanied by
a slide presentation. A webcast replay will be available on
the AcelRx website for 90 days following the call by visiting the
Investor page of the company's website at www.acelrx.com.
Investors who wish to participate in the conference call may do
so by dialing (866) 361-2335 for domestic callers, (855) 669-9657
for Canadian callers, or (412) 902-4204 for international
callers.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles.
AcelRx has one approved product in the U.S., DSUVIA®
(sufentanil sublingual tablet, 30 mcg), known as DZUVEO®
in Europe, indicated for the
management of acute pain severe enough to require an opioid
analgesic for adult patients in certified medically supervised
healthcare settings, and one product candidate, Zalviso®
(sufentanil sublingual tablet system, SST system, 15 mcg), an
investigational product in the U.S., is being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings. AcelRx has obtained the rights to file New Drug
Applications (NDAs) and, subject to U.S. Food and Drug
Administration (FDA) approval, commercialize in the U.S. two of
Laboratoire Aguettant's innovative, EU-approved, pre-filled syringe
products – ready-to-use ephedrine and phenylephrine. DZUVEO and
Zalviso are both approved products in Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-third-quarter-2021-financial-results-call-and-webcast-on-november-15-2021-301421014.html
SOURCE AcelRx Pharmaceuticals, Inc.